Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?

被引:82
作者
Dagan, T
Sable, C
Bray, J
Gerschenson, M
机构
[1] NHLBI, Div Heart & Vasc Dis, NIH, Bethesda, MD 20892 USA
[2] Childrens Natl Med Ctr, Dept Cardiol, Washington, DC 20010 USA
[3] George Washington Univ, Sch Publ Hlth & Hlth Serv, Ctr Hlth Serv Res & Policy, Forum Collaborat HIV Res, Washington, DC 20006 USA
关键词
cardiovascular; hepatic; human immunodeficiency virus; lactic acidosis; lipodystrophy; myopathies; neuropathy; nucleoside analog reverse transcriptase inhibitors; pancreatitis;
D O I
10.1016/S1567-7249(02)00003-X
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mitochondrial dysfunction has been associated with long-term toxicities of human immunodeficiency virus (HIV) therapy, particularly with the nucleoside analog reverse transcriptase inhibitors (NRTIs). Lactic acidosis, hepatic steatosis, myopathies, cardiomyopathies, neuropathies, and lipodystrophy are frequently attributed to mitochondrial toxicity. Since mitochondrial toxicity could pose a major threat to the long-term success of HIV therapy, the scientific evidence underlying an association between mitochondrial toxicity and antiretroviral therapies, must be carefully examined. There is some data to support the association between NRTIs and mitochondria dysfunction. In this review, we examine human, animal, and in vitro data implicating mitochondrial dysfunction as the causal mechanism of NRTI-associated toxicity in HIV-infected patients. Published by Elsevier Science B.V. and Mitochondria Research Society.
引用
收藏
页码:397 / 412
页数:16
相关论文
共 134 条
  • [21] Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors
    Brinkman, K
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 167 - 169
  • [22] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [23] Management of hyperlactatemia: no need for routine lactate measurements
    Brinkman, K
    [J]. AIDS, 2001, 15 (06) : 795 - 797
  • [24] Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
    Brinkman, K
    ter Hofstede, HJM
    Burger, DM
    Smeitinkt, JAM
    Koopmans, PP
    [J]. AIDS, 1998, 12 (14) : 1735 - 1744
  • [25] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32
  • [26] Adverse effects of antiretroviral therapy
    Carr, A
    Cooper, DA
    [J]. LANCET, 2000, 356 (9239) : 1423 - 1430
  • [27] Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection
    Cepeda, JA
    Wilks, D
    [J]. AIDS, 2000, 14 (03) : 332 - 333
  • [28] CHANG CN, 1992, J BIOL CHEM, V267, P414
  • [29] DETERMINATION OF THE BLOOD LACTATE-PYRUVATE RATIO AS A NONINVASIVE TEST FOR THE DIAGNOSIS OF ZIDOVUDINE MYOPATHY
    CHARIOT, P
    MONNET, I
    MOUCHET, M
    ROHR, M
    LEFAUCHEUR, JP
    DUBREUILLEMAIRE, ML
    CHOUSTERMAN, M
    GHERARDI, R
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (04): : 583 - 586
  • [30] Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
    Chariot, P
    Drogou, I
    de Lacroix-Szmania, I
    Eliezer-Vanerot, MC
    Chazaud, B
    Lombès, A
    Schaeffer, A
    Zafrani, ES
    [J]. JOURNAL OF HEPATOLOGY, 1999, 30 (01) : 156 - 160